China’s drug regulator has granted the first global approval for a novel, internationally trialled medicine, beating regulatory authorities in the United States, Japan, and Europe to the milestone.
The decision marks a historic breakthrough for the country's pharmaceutical sector as Beijing doubles down on biopharmaceuticals to serve as a key driver of economic growth.
In-depth summary · AI, neutral